topic

850 Immunological considerations for developing optimal whole tumor cell-derived cancer vaccines
Flavio Salazar Onfray

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A506-A507; DOI: 10.1136/jitc-2020-SITC2020.0850
855 Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses
Thomas Le, Subuhi Kaul, Shannon Wongvibulsin, Laura Cappelli, Jarushka Naidoo, Yevgeniy Semenov, Shawn Kwatra

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A509-A510; DOI: 10.1136/jitc-2020-SITC2020.0855
857 LAMP1 targeting of the large T antigen of merkel cell polyomavirus elicits potent CD4+ T cell responses and prevents tumor growth
Claire Buchta Rosean, Claire Buchta Rosean, Pratima Sinha, David Koelle, Paul Nghiem, Teri Heiland

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A510-A511; DOI: 10.1136/jitc-2020-SITC2020.0857
861 Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells
Andrew Rankin, Edwina Naik

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A512-A513; DOI: 10.1136/jitc-2020-SITC2020.0861
868 PRELP-facilitated enhancement of MHC class I surface expression in B16F10 melanoma cells
Helene Schäfer, Karthikeyan Subbarayan, Barbara Seliger

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A515-A516; DOI: 10.1136/jitc-2020-SITC2020.0868
102 Cord-blood derived NK cells, and CAR-T cells, an attractive improved immunotherapy treatment to be considered for hematological malignancies
Mireia Bachiller García, Lorena Pérez-Amill, Anthony Battram, Alvaro Urbano-Ispizua, Beatriz Martín-Antonio

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A64; DOI: 10.1136/jitc-2020-SITC2020.0102
105 A third-generation human GUCY2C-targeted CAR-T cell for colorectal cancer immunotherapy
Trevor Baybutt, Adam Snook, Scott Waldman, Jonathan Stem, Ellen Caparosa, Alicja Zalewski

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A65-A66; DOI: 10.1136/jitc-2020-SITC2020.0105
104 BCMA-targeting CAR-T cells expanded in IL-15 have an improved phenotype for therapeutic use compared to those grown in IL-2 or IL-15/IL-7
Anthony Battram, Mireia Bachiller, Álvaro Urbano-Ispizua, Beatriz Martin-Antonio

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A65; DOI: 10.1136/jitc-2020-SITC2020.0104
123 Natural killer cells engineered with an inducible, responsive genetic construct targeting TIGIT and CD73 to relieve immunosuppression within the GBM microenvironment
Kyle Lupo, Sandro Matosevic

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A74-A75; DOI: 10.1136/jitc-2020-SITC2020.0123
127 Preclinical evaluation of NKX019, a CD19-targeting CAR NK Cell
Nadege Morisot, Sarah Wadsworth, Tina Davis, Nicole Dailey, Kyle Hansen, Denise Gonzalez, Nafees Rahman, Alex Aronov, Y Fan, Chao Guo, Luxuan Buren, Anmol Vohra, Kate Jamboretz, H Leman, Sasha Lazetic, Ivan Chan, James Trager, Joanne Tan

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A78; DOI: 10.1136/jitc-2020-SITC2020.0127

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages